作者
Kai Cao,Yingda Xia,Jiawen Yao,Xu Han,Lukáš Lambert,Tingting Zhang,Wei Tang,Gang Jin,Hui Jiang,Xu Fang,Isabella Nogues,Xuezhou Li,Wenchao Guo,Yu Wang,Wei Fang,Mingyan Qiu,Yang Hou,Tomáš Kovárník,Michal Vočka,Yimei Lu,Yingli Chen,Xin Chen,Zaiyi Liu,Jian Zhou,Chuanmiao Xie,Rong Zhang,Hong Lu,Gregory D. Hager,Alan Yuille,Le Lü,Chengwei Shao,Yu Shi,Qi Zhang,Yong‐Min Liang,Ling Zhang,Jianping Lu
摘要
Abstract Pancreatic ductal adenocarcinoma (PDAC), the most deadly solid malignancy, is typically detected late and at an inoperable stage. Early or incidental detection is associated with prolonged survival, but screening asymptomatic individuals for PDAC using a single test remains unfeasible due to the low prevalence and potential harms of false positives. Non-contrast computed tomography (CT), routinely performed for clinical indications, offers the potential for large-scale screening, however, identification of PDAC using non-contrast CT has long been considered impossible. Here, we develop a deep learning approach, pancreatic cancer detection with artificial intelligence (PANDA), that can detect and classify pancreatic lesions with high accuracy via non-contrast CT. PANDA is trained on a dataset of 3,208 patients from a single center. PANDA achieves an area under the receiver operating characteristic curve (AUC) of 0.986–0.996 for lesion detection in a multicenter validation involving 6,239 patients across 10 centers, outperforms the mean radiologist performance by 34.1% in sensitivity and 6.3% in specificity for PDAC identification, and achieves a sensitivity of 92.9% and specificity of 99.9% for lesion detection in a real-world multi-scenario validation consisting of 20,530 consecutive patients. Notably, PANDA utilized with non-contrast CT shows non-inferiority to radiology reports (using contrast-enhanced CT) in the differentiation of common pancreatic lesion subtypes. PANDA could potentially serve as a new tool for large-scale pancreatic cancer screening.